Results. Clinical reports of transplant recipients
|
|
- Sara Paul
- 6 years ago
- Views:
Transcription
1 Cloning of EBV genes as fusion proteins with Renilla luciferase for Luciferase Immunoprecipitation System (LIPS) analysis A panel of 13 different EBV proteins was generated as Renilla luciferase (Ruc) fusion protein for serological EBV testing using LIPS. In addition to the previously described N-terminal EBV antigen fusions of gp350 constructed in the pren3s vector and the C-terminal fusion of BZLF2 constructed in pren2, 1 11 new EBV proteins were generated in pren2 vector and included BLRF2 (p23), BFRF3 (p18), BMRF1, BMLF1, BZLF1, BHRF, BALF1, BKRF2, BMLF1, BCRF1, and LMP2A. The coding sequences of these EBV proteins were amplified by PCR from genomic DNA with gene specific linker-primer adapters and then the corresponding cdna fragments were subcloned downstream of Ruc. The sequence of the primer-linker oligonucleotides used for amplification are as follows: BLRF2; 5 -GAGAGATCTAGTG GGCAGCAGAGAGGC and 5 -GAGCTCG AGTTAATCAGAAATTTGCAC, BFRF3: 5 -GAGGGATCCGC ACGCCGGCTGCC CAAG and 5 -GAGCTCGAGCTACTGTTT CT TACGTGC, BMRF1; 5 -GAGGGATCCCCTGAATTTGTTAAGCTC and 5 -GAG CTCGAGTTAA ATGAGGGGGTTAAAG, BMLF1; 5 -GAGAGATCTGTTC CTTC TCAGAGACTCTCC and 5 -GAGGTCGACTTATTGATTTAATCCAGGAAC, BHRF1; 5 -GAGAGATCTGCCTATTCAACAAGGGAG and 5 -GAGCTCGAGTTA GTGTCTTCCT CTGGAG, and EBNA1; 5 -GAGGGATCCTCTGACGAGGGGCCAG GT and 5 -GAGCTCGAGTCACTCCTGCCCTTCCTC. Additional details for primers and nucleotide/ protein sequences for all the constructs are available upon request. Results Clinical reports of transplant recipients Patient 9 A 17-year-old white man presented with fatigue, myalgias, fever, and pancytopenia. The symptoms initially resolved, but recurred and included hepatitis, splenomegaly, encephalitis, peripheral neuropathy, facial palsy. EBV serologies showed evidence of prior infection. He was treated with acyclovir, intravenous immune globulin (IVIG), and corticosteroids. He developed diplopia and peripheral neuropathy and an MRI showed multiple cerebellar and cerebral lesions. IFN-β was added, and an MRI showed demyelinating lesions in the thoracic spine and a lymph node biopsy showed hemophagocytosis. He was treated with acyclovir, corticosteroids, and cyclosporine and underwent splenectomy which showed hemophagocytosis; many cells contained EBV RNA. CT scans showed lymphadenopathy and a lesion in the liver; biopsies of a lymph node and liver were positive for EBV RNA. He was treated with corticosteroids and azathioprine. Bone marrow and liver biopsies showed an EBV-positive lymphohistiocytic T-cell infiltrate. He was treated with azathioprine, corticosteroids and IVIG, followed by etoposide, cytosine arabinoside, cyclophosphamide, antithymocyte globulin, and total body irradiation. He underwent an allogeneic transplant using bone marrow from a matched unrelated donor while the liver lesion was progressing. His liver lesion resolved and his course was complicated by mild GVHD. He is currently 11 years post-transplant on no immunosuppressive therapy and his EBV serology and EBV blood PCR remains negative.
2 Patient 12 A 55-year-old white man presented with fever, chills, lymphadenopathy, and splenomegaly. Serologies were consistent with prior EBV infection. His symptoms responded to prednisone; however, an auxiliary lymph node showed a polymorphic B cell lymphoma composed of CD20 + and CD20 B cells; the tumor cells were positive for EBV RNA. He developed arthralgia, lymphadenopathy, splenomegaly, anterior uveitis, peripheral neuropathy, and rash over the upper extremities. A skin biopsy showed a perivascular lymphocytic infiltrate that was positive for EBV RNA. PCR of the peripheral blood showed 500,860 EBV copies per 10 6 cells. A lumbar puncture showed atypical lymphocytes and PCR was positive for EBV DNA. He was treated with IFN-α at doses up to 25 million units three times a week and after a transient response his symptoms returned and viral load rose to 10 6 EBV copies per 10 6 cells. Bortezomib was added to IFN-α therapy, but was discontinued because of gastrointestinal side effects. IVIG was given for peripheral neuropathy thought to be secondary to SCAEBV. He received autologous EBVspecific cytotoxic T cells and rituximab, but without a sustained response. He received two courses of EPOCH chemotherapy (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin) with rituximab and fludarabine, and while there was a transient improvement in symptoms and EBV viral load, his symptoms and EBV load subsequently increased. He received cyclophosphamide and fludarabine followed by allogeneic transplant using peripheral blood stem cells from an HLA-matched sibling. Due to low blood cell counts, he received a boost of stem cells from the same donor. His symptoms resolved and his viral load became undetectable, then spiked to 220,000 EBV copies per 10 6 cells and rapidly declined to undetectable again. His posttransplant course was complicated by Aspergillus pneumonia, toxoplasmosis encephalitis, adrenal insufficiency, and GVHD of the liver. He is currently 6 years post-transplant and EBV PCR in the blood is undetectable. Patient 13 A 44-year-old white man presented with a diffuse abdominal rash, fever, pancytopenia, and pulmonary nodules. Serology was consistent with prior EBV infection. The CD4 count was 223 and NK cell count 5. A CT scan showed diffuse lymphadenopathy and splenomegaly. A lymph node biopsy showed a polymorphic B cell infiltrate with EBV-positive immunoblasts; with CD20 + and CD20 EBV-positive B cells. The EBV DNA in the blood was 290,000 EBV copies per 10 6 cells. He was treated with IFN-α, but had persistent lymphadenopathy. His blood showed 1,700,000 EBV copies per 10 6 cells and CSF showed 310,000 copies per 10 6 cells. He was treated with bortezomib and ganciclovir, but his viral load remained elevated at 800,000 EBV copies per 10 6 cells. His lymphadenopathy, and pulmonary nodules persisted, and he was treated with EPOCH and rituximab. Hemophagocytosis was noted in the bone marrow. He received additional courses of rituximab and developed polyneuropathy. Due to persistent disease, he received cyclophosphamide and fludarabine and underwent allogeneic transplant using peripheral blood stem cells from a sibling. While his lymphandenopathy, pulmonary nodules, and viral load declined, he developed septic shock, multiorgan failure, hemophagocytic syndrome, central pontine myelinolysis, and died on post-transplant day 20. At the time of death the EBV PCR of the blood was negative. At autopsy there was EBV-positive lymphoma in the lung, liver, lymph nodes, kidneys, pancreas, and spleen that was largely necrotic indicating a response to the transplant.
3 Patient 15 This patient was previously reported in reference 16. Patient 16 A 29-year-old white man presented with fever, night sweats, and malaise, and diffuse lymphadenopathy. His symptoms resolved, but recurred soon thereafter and a cervical lymph node showed a polymorphic EBV-positive lymphoproliferative disorder with both CD20 + and CD20 cells and necrosis. EBV RNA was detected in B cells. His symptoms recurred nearly monthly and responded to prednisone. A bone marrow showed EBV-positive cells and blood showed 46,000 EBV copies per 10 6 cells. He was treated with rituximab and his symptoms resolved and EBV DNA declined, but fever and lymphadenopathy recurred. A lymph node biopsy showed progressive disease and increasing numbers of CD20-negative B cells. He received IFN-α (up to 20 MU 3 times weekly), but had persistent lymphadenopathy and fever. A lymph node biopsy showed polymorphic B cell lymphoma and he received EPOCH and ritxuimab. Additional studies showed impaired NK cell function and he received additional chemotherapy and fludarabine followed by an allogeneic transplant using peripheral blood stem cells from a sibling. He failed to engraft and received donor lymphocyte infusion and stem cell boosts. He developed pulmonary nodules that were positive for EBV by PCR and liver disease consistent with progressive EBV lymphoproliferative disease. He received a second allogeneic transplant using peripheral blood stem cells from a matched unrelated donor after fludarabine and total body irradiation and developed progressive hepatic failure with erythrophagocytosis in the liver, renal failure, and failure to engraft. At autopsy lymphoma was present in the lungs, liver, kidney, and mediastinal lymph nodes. Patient 17 A 5-year-old Hispanic girl presented with fever, sinusitis, and lymphadenopathy. A bone marrow showed hemophagocytosis and she was treated with etoposide, dexamethasone, and cyclosporine. Her symptoms recurred the EBV DNA in the blood was 2,189,000 copies/μg of DNA. The EBV IgG was >1:10,240 and EBV VCA IgM was <10. A lymph node biopsy showed EBV-positive B cell lymphoproliferative disease and she was treated with rituximab with a good response. Two years later the disease recurred with fever, lymphadenopathy, mediastinal mass and an EBV DNA viral load of 51,000 copies/μg of DNA. A lymph node biopsy again showed EBV lymphoproliferative disease and she received two additional doses of rituximab and her EBV DNA viral load became undetectable. Six months later the mediastinal mass increased in size and her EBV DNA viral load increased to 5,000 copies/μg of DNA and she received two doses of autologous EBV-specific cytotoxic T cells and rituximab. The following year an iliac crest mass showed an EBV-positive polymorphic B cell lymphoma. She was treated with chemotherapy (vincristine, doxorubicin, methotrexate and prednisone), but due to persistent lymphadenopathy she underwent conditioning with busulphan, cyclophosphamide, cytosine arabinoside, and alemtuzumab (campath) and received a matched, unrelated donor bone marrow transplant. Her course was complicated by fever and elevated serum transaminases at the time of engraftment, and she developed an atypical mycobacteria infection involving the skin and lungs which responded to antibiotic therapy. She has returned to school and is currently 5 years post transplant. Her EBV DNA viral load has remained low or undetectable.
4 Patient 18 A 4-year-old Vietnamese boy presented with fever, lymphadenopathy, conjunctivitis, red lips, and swollen feet. The EBV IgG was >1:10,240 and the bone marrow showed EBV DNA. He was treated with IVIG, acyclovir, and prednisone. His symptoms resolved, then recurred 3 years later and also included hepatosplenomegaly, anemia, and hepatitis. A liver biopsy showed T cell CAEBV, and the EBV DNA in the blood was 115,327 copies/μg of DNA. He was treated with decadron, etoposide, and cyclosporine without response. He underwent allogeneic transplant using bone marrow obtained from his identical twin. He developed fever and pleural effusions, and his EBV DNA rose to 1,219 copies/μg of DNA. He was treated with donor lymphocytes followed by several courses of donor derived EBV-specific CTLs. A lymph node biopsy showed T cell EBV-positive lymphoproliferative disease and he received additional donor lymphocytes, anti-cd45 monoclonal antibody, and EBV LMP-2 specific CTLs. The EBV viral DNA ranged from 100,000 to 150,000 copies/μg of DNA and he had generalized lymphadenopathy. A repeat lymph node biopsy showed T cell CAEBV and his disease progressed and he died of EBVpositive T-cell lymphoma. Patient 19 A 7-year-old Hispanic boy presented with hypersensitivity to mosquito bites with subsequent ulcerations requiring skin grafting. EBV DNA was present in NK cells in a skin biopsy. The EBV DNA was >262,144 copies per ug of DNA and the EBV VCA was 1:320. NK cells were present in 47% of the peripheral blood lymphocytes. He did not respond to EBV-specific CTLs and he received an allogeneic transplant using peripheral blood stem cells from a matched unrelated donor at age 12. Initially his EBV DNA was undetected, but when it rose to 5,458 he received EBV-specific T cells and his PCR has remained undetectable and he is currently 2 years posttransplant. REFERENCES 1. Sashihara J, Burbelo PD, Savoldo B, Pierson TC, Cohen JI. Human antibody titers to Epstein- Barr virus (EBV) gp350 correlate with neutralization of infectivity better than antibody titers to EBV gp42 using a rapid flow cytometry-based EBV neutralization assay, Virology, 2009;391:
5 Table S1. EBV serologies Patient EBV VCA IgM a EBV VCA IgA EBV EA-D Unknown if B, T, or NK cell disease 1 1:40,<1:8 1:640 1:5,120 2 <1:8 1:640 1:20,480 4 ND 1:160 1:1, :8 ND <1:10 B-cell disease 3 <1:8 1:320 1:20, :8, <1:8 ND 1:5, :1,024, 1:16 1:8 1:10,240 8 <1:8 1:256 1:2,560 9 <1:8 1:256 1: negative ND 1:163, negative ND ND 13 negative ND ND 14 positive, negative ND ND 16 negative ND ND 17 <10 ND ND T-cell disease 10 <1:8 1:1,024 1:10, negative ND ND 18 ND ND ND NK-cell disease 19 negative ND ND a Some laboratories report a titer for VCA IgM and other report results as negative or positive based on ELISA assay. EBV, viral capsid antigen; EA-D, early antigen-diffuse; ND, not done.
Severe Viral Related Complications Following Allo-HCT for Severe Aplastic Anemia
Severe Viral Related Complications Following Allo-HCT for Severe Aplastic Anemia Liat Shragian Alon, MD Rabin Medical Center, ISRAEL #EBMT15 www.ebmt.org Patient: 25-year-old male No prior medical history
More informationClinical Aspect and Application of Laboratory Test in Herpes Virus Infection. Masoud Mardani M.D,FIDSA
Clinical Aspect and Application of Laboratory Test in Herpes Virus Infection Masoud Mardani M.D,FIDSA Shahidhid Bh BeheshtiMdi Medical lui Universityit Cytomegalovirus (CMV), Epstein Barr Virus(EBV), Herpes
More information2017 CST-Astellas Canadian Transplant Fellows Symposium. EBV Post Transplantation Implications and Approach to Management
2017 CST-Astellas Canadian Transplant Fellows Symposium EBV Post Transplantation Implications and Approach to Management Atul Humar, MD Atul Humar is a Professor in the Department of Medicine, University
More informationPUO in the Immunocompromised Host: CMV and beyond
PUO in the Immunocompromised Host: CMV and beyond PUO in the immunocompromised host: role of viral infections Nature of host defect T cell defects Underlying disease Treatment Nature of clinical presentation
More informationEBV in HSCT 2015 update of ECIL guidelines
ECIL-6 EBV in HSCT 2015 update of ECIL guidelines Jan Styczynski (Poland, chair), Walter van der Velden (Netherlands), Christopher Fox (United Kingdom), Dan Engelhard (Israel), Rafael de la Camara (Spain),
More informationInfectious Mononucleosis The Virus Pathophysiology: Age: History: Fever. Lymphadenopathy
Infectious Mononucleosis The Virus A member of the Herpesvirus family Infects human B lymphocytes Herpes viruses contain double-stranded DNA, and they have an icosahedral capsid and a glycoprotein-containing
More informationStem cell transplantation. Dr Mohammed Karodia NHLS & UP
Stem cell transplantation Dr Mohammed Karodia NHLS & UP The use of haemopoeitic stem cells from a donor harvested from peripheral blood or bone marrow, to repopulate recipient bone marrow. Allogeneic From
More informationEpstein-Barr Virus 1
Epstein-Barr Virus 1 Herpesviruses dsdna, linear, enveloped, 180-200 nm Large genome, codes for 75 viral proteins 50-70% similarity Cross reactivity between HSV and VZV HSV-2 virus particle. Note that
More informationCity Pediatric Meet-Dec 2011 SPECTRUM OF HLH. Spectrum of HLH. Dr.Revathi Raj s unit, Apollo Children s Hospital.
City Pediatric Meet-Dec 2011 SPECTRUM OF HLH Spectrum of HLH Dr.Revathi Raj s unit, Apollo Children s Hospital. Case 1 4 month male child /thriving well Fever - 5 days with cough O/E hepatospenomegaly
More informationForm 2033 R3.0: Wiskott-Aldrich Syndrome Pre-HSCT Data
Key Fields Sequence Number: Date Received: - - CIBMTR Center Number: CIBMTR Recipient ID: Has this patient's data been previously reported to USIDNET? USIDNET ID: Today's Date: - - Date of HSCT for which
More informationNephrology Grand Rounds
Nephrology Grand Rounds PTLD in Kidney Transplantation Charles Le University of Colorado 6/15/12 Objectives Background Pathogenesis Epidemiology and Clinical Manifestation Incidence Risk Factors CNS Lymphoma
More informationIndolent Lymphomas. Dr. Melissa Toupin The Ottawa Hospital
Indolent Lymphomas Dr. Melissa Toupin The Ottawa Hospital What does indolent mean? Slow growth Often asymptomatic Chronic disease with periods of relapse (long natural history possible) Incurable with
More informationEpstein-Barr Virus in a Toddler. Elaine Bullock, MD Pediatrics LSU Health Shreveport Louisiana Chapter AAP Pediatric Potpourri on the Bayou
Epstein-Barr Virus in a Toddler Elaine Bullock, MD Pediatrics LSU Health Shreveport Louisiana Chapter AAP Pediatric Potpourri on the Bayou Disclosure Presenter: Elaine Bullock, MD I have nothing to disclose
More informationEBV Protocol
EBV Protocol 8.26.14 Data From UNOS Summary Stats 1988-2014 CASU + 2009-2014 CAPC Organ Total PTLD Percent PTLD Percent PTLD in Literature Heart 294 21 7 3-9 Heart-Lung 34 3 9 16 Intestine 42 7 17 10-45
More informationClass 10. DNA viruses. I. Seminar: General properties, pathogenesis and clinial features of DNA viruses from Herpesviridae family
English Division, 6-year programme Class 10 DNA viruses I. Seminar: General properties, pathogenesis and clinial features of DNA viruses from Herpesviridae family II. Assays to be performed: 1. Paul-Bunnel-Davidsohn
More informationCase Report Epstein-Barr Virus Infection in an Elderly Nonimmunocompromised Adult Successfully Treated with Rituximab
Case Reports in Hematology, Article ID 641483, 4 pages http://dx.doi.org/10.1155/2014/641483 Case Report Epstein-Barr Virus Infection in an Elderly Nonimmunocompromised Adult Successfully Treated with
More informationTransplantation. Immunology Unit College of Medicine King Saud University
Transplantation Immunology Unit College of Medicine King Saud University Objectives To understand the diversity among human leukocyte antigens (HLA) or major histocompatibility complex (MHC) To know the
More informationInstructions for Chronic Lymphocytic Leukemia Post-HSCT Data (Form 2113)
Instructions for Chronic Lymphocytic Leukemia Post-HSCT Data (Form 2113) This section of the CIBMTR Forms Instruction Manual is intended to be a resource for completing the CLL Post-HSCT Data Form. E-mail
More informationTransplantation Immunology Booklet C
Booklet C Pretest Correct Answers 3. (C) is correct. One of the major barriers to successful hematopoietic stem cell transplantation is the antigens coded for by the major histocompatibility gene complex.
More informationIndolent Lymphomas: Current. Dr. Laurie Sehn
Indolent Lymphomas: Current Dr. Laurie Sehn Why does indolent mean? Slow growth Often asymptomatic Chronic disease with periods of relapse (long natural history possible) Incurable with current standard
More informationMANTLE CELL LYMPHOMA
MANTLE CELL LYMPHOMA CLINICAL CASE PRESENTATION Martin Dreyling Medizinische Klinik III LMU München Munich, Germany esmo.org Multicenter Evaluation of MCL Annency Criteria fulfilled event free interval
More information4100: Cellular Therapy Essential Data Follow-Up Form
4100: Cellular Therapy Essential Data Follow-Up Form Registry Use Only Sequence Number: Date Received: Key Fields CIBMTR Center Number: Event date: Visit: 100 day 6 months 1 year 2 years >2 years, Specify:
More information3/6/2017. Treatment of Detected Antibodies. I have financial relationship(s) with: Thoratec/St. Jude/Abbott Consultant CareDx Consultant/Speaker
Treatment of Detected Antibodies Sean Pinney, MD Director, Advanced Heart Failure & Transplantation Mount Sinai Hospital New York, NY Sean Pinney, MD Associate Professor of Medicine Icahn School of Medicine
More informationCase conference. Welcome Dr. Lawrence Tierney
Case conference Welcome Dr. Lawrence Tierney Case: 18 year-old male CC) hamatomesis, Fever and cough HPI) 1 st admission One month ago, he admitted to our hospital because of hematemesis. He had weight
More informationHodgkin's Lymphoma. Symptoms. Types
Hodgkin's lymphoma (Hodgkin's disease) usually develops in the lymphatic system, a part of the body's immune system. This system carries disease-fighting white blood cells throughout the body. Lymph tissue
More informationEBV Infection and Immunity. Andrew Hislop Institute for Cancer Studies University of Birmingham
EBV Infection and Immunity Andrew Hislop Institute for Cancer Studies University of Birmingham EBV Introduction Large ds DNA virus Spread by saliva contact Lifelong infection Predominantly B-lymphotropic
More informationLYMPHOMA Joginder Singh, MD Medical Oncologist, Mercy Cancer Center
LYMPHOMA Joginder Singh, MD Medical Oncologist, Mercy Cancer Center Lymphoma is cancer of the lymphatic system. The lymphatic system is made up of organs all over the body that make up and store cells
More informationDr. Yi-chi M. Kong August 8, 2001 Benjamini. Ch. 19, Pgs Page 1 of 10 TRANSPLANTATION
Benjamini. Ch. 19, Pgs 379-399 Page 1 of 10 TRANSPLANTATION I. KINDS OF GRAFTS II. RELATIONSHIPS BETWEEN DONOR AND RECIPIENT Benjamini. Ch. 19, Pgs 379-399 Page 2 of 10 II.GRAFT REJECTION IS IMMUNOLOGIC
More informationDiagnosis of CMV infection UPDATE ECIL
UPDATE ECIL-4 2011 Recommendations for CMV and HHV-6 management in patients with hematological diseases Per Ljungman, Rafael de la Camara, Hermann Einsele, Dan Engelhard, Pierre Reusser, Jan Styczynski,
More informationEBV and Infectious Mononucleosis. Infectious Disease Definitions. Infectious Diseases
Infectious Disease Definitions Infection when a microorganism invades a host and multiplies enough to disrupt normal function by causing signs and symptoms Pathogencity ability of an organism to cause
More informationMabThera. SC. The wait is over. MabThera delivered in just 5 minutes. SC= subcutaneous injection
MabThera SC. The wait is over. MabThera delivered in just 5 minutes Abbreviated Prescribing Information MabThera 1400 mg solution for subcutaneous (SC) injection (Rituximab) Indications: Indicated in adults
More informationCanine Histiocytic Disorders DR. MEREDITH GAUTHIER, DVM DACVIM (ONCOLOGY) OCTOBER 29, 2015
Canine Histiocytic Disorders DR. MEREDITH GAUTHIER, DVM DACVIM (ONCOLOGY) OCTOBER 29, 2015 Canine Histiocytes! Cells derived from CD34+ stem cells and blood monocytes! Macrophages! Dendritic cells (DC)!
More informationThe Pulmonary Pathology of Iatrogenic Immunosuppression. Kevin O. Leslie, M.D. Mayo Clinic Scottsdale
The Pulmonary Pathology of Iatrogenic Immunosuppression Kevin O. Leslie, M.D. Mayo Clinic Scottsdale The indications for iatrogenic immunosuppression Autoimmune/inflammatory disease Chemotherapy for malignant
More informationOne Day BMT Course by Thai Society of Hematology. Management of Graft Failure and Relapsed Diseases
One Day BMT Course by Thai Society of Hematology Management of Graft Failure and Relapsed Diseases Piya Rujkijyanont, MD Division of Hematology-Oncology Department of Pediatrics Phramongkutklao Hospital
More informationCASE REPORT. Abstract. Introduction. Methods
CASE REPORT Recurrence of Chronic Active Epstein-Barr Virus Infection from Donor Cells after Achieving Complete Response Through Allogeneic Bone Marrow Transplantation Ayako Arai 1, Ken-Ichi Imadome 2,
More informationAggressive Lymphomas - Current. Dr Kevin Imrie Physician-in-Chief, Sunnybrook Health Sciences Centre
Aggressive Lymphomas - Current Dr Kevin Imrie Physician-in-Chief, Sunnybrook Health Sciences Centre Conflicts of interest I have no conflicts of interest to declare Outline What does aggressive lymphoma
More informationHaemophagocytic lymphohistiocytosis (HLH)
HLH Haemophagocytic lymphohistiocytosis (HLH) Information for families hello@piduk.org 0800 987 8986 www.piduk.org About this leaflet This booklet has been produced jointly between PID UK, Great Ormond
More informationCase Report Traumatic Haemorrhagic Cervical Lymphadenopathy with Underlying Infectious Mononucleosis
Hindawi Case Reports in Radiology Volume 2017, Article ID 3097414, 4 pages https://doi.org/10.1155/2017/3097414 Case Report Traumatic Haemorrhagic Cervical Lymphadenopathy with Underlying Infectious Mononucleosis
More information5/9/2018. Bone marrow failure diseases (aplastic anemia) can be cured by providing a source of new marrow
5/9/2018 or Stem Cell Harvest Where we are now, and What s Coming AA MDS International Foundation Indianapolis IN Luke Akard MD May 19, 2018 Infusion Transplant Conditioning Treatment 2-7 days STEM CELL
More informationTalk overview. Case 1. Case Examples 21/07/2017. Epstein Barr Virus (EBV) quantification in health and disease Bit of background Recent case examples
Belfast Pathology 2017 EBV Quantification in health and disease Talk overview Epstein Barr Virus (EBV) quantification in health and disease Bit of background Recent case examples Susan Feeney PhD FRCPath
More informationLarge cell immunoblastic Diffuse histiocytic (DHL) Lymphoblastic lymphoma Diffuse lymphoblastic Small non cleaved cell Burkitt s Non- Burkitt s
Non Hodgkin s Lymphoma Introduction 6th most common cause of cancer death in United States. Increasing in incidence and mortality. Since 1970, the incidence of has almost doubled. Overview The types of
More informationEpstein Barr Virus Infection and Posttransplant Lymphoproliferative Disorder
American Journal of Transplantation 2013; 13: 41 54 Wiley Periodicals Inc. Continuing Medical Education C Copyright 2013 The American Society of Transplantation and the American Society of Transplant Surgeons
More informationMantle-Cell Leukemia: Lessons in Life and Death
Mantle-Cell Leukemia: Lessons in Life and Death James J. Stark, MD, FACP Medical Director, Cancer Program and Palliative Care Maryview Medical Center Professor of Medicine, EVMS Case Presentation 60 y.o.
More information3.1 Clinical safety of chimeric or humanized anti-cd25 (ch/anti-cd25)
3 Results 3.1 Clinical safety of chimeric or humanized anti-cd25 (ch/anti-cd25) Five infusions of monoclonal IL-2 receptor antibody (anti-cd25) were planned according to protocol between day 0 and day
More informationAdverse effects of Immunotherapy. Asha Nayak M.D
Adverse effects of Immunotherapy Asha Nayak M.D None Financial Disclosures Objectives Understand intensity of the AEs. Understanding unique side-effects. Develop effective monitoring and management guidelines.
More informationComplications after HSCT. ICU Fellowship Training Radboudumc
Complications after HSCT ICU Fellowship Training Radboudumc Type of HSCT HSCT Improved outcome due to better HLA matching, conditioning regimens, post transplant supportive care Over one-third have pulmonary
More informationBIT 120. Copy of Cancer/HIV Lecture
BIT 120 Copy of Cancer/HIV Lecture Cancer DEFINITION Any abnormal growth of cells that has malignant potential i.e.. Leukemia Uncontrolled mitosis in WBC Genetic disease caused by an accumulation of mutations
More informationWarm Autoantibodies in a Patient with Hemophagocytic Lymphohistiocytosis: A Case Report
Warm Autoantibodies in a Patient with Hemophagocytic Lymphohistiocytosis: A Case Report Emily Coberly, MD Department of Pathology and Anatomical Sciences University of Missouri Columbia April 30, 2013
More informationOverview of New Approaches to Immunosuppression in Renal Transplantation
Overview of New Approaches to Immunosuppression in Renal Transplantation Ron Shapiro, M.D. Professor of Surgery Surgical Director, Kidney/Pancreas Transplant Program Recanati/Miller Transplantation Institute
More informationCase Report Lymph Node Flow Cytometry as a Prompt Recognition of Ultra Early Onset PTLD: A Successful Case of Rituximab Treatment
Case Reports in Hematology Volume 2015, Article ID 430623, 5 pages http://dx.doi.org/10.1155/2015/430623 Case Report Lymph Node Flow Cytometry as a Prompt Recognition of Ultra Early Onset PTLD: A Successful
More informationImmunosuppressants. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia
Immunosuppressants Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia Immunosuppressive Agents Very useful in minimizing the occurrence of exaggerated or inappropriate
More informationTrends in Hematopoietic Cell Transplantation. AAMAC Patient Education Day Oct 2014
Trends in Hematopoietic Cell Transplantation AAMAC Patient Education Day Oct 2014 Objectives Review the principles behind allogeneic stem cell transplantation Outline the process of transplant, some of
More informationFever of unknown origin
Fever of unknown origin Case B History of the present illness 75 years old women presented at our hospital with since months daily fevers between 38 to 39.5 Celsius (100.4-103.1 F) with night sweats. Her
More informationHỘI CHỨNG THỰC BÀO MÁU. (HEMOPHAGOCYTIC LYMPHOHISTOCYTOSIS)
HỘI CHỨNG THỰC BÀO MÁU. (HEMOPHAGOCYTIC LYMPHOHISTOCYTOSIS) INTRODUTION. An aggressive and life-threatening syndrome of excessive immune activation. Was described in 1952. Most frequently affects infants
More informationDr Sophia Davies. Birmingham Heartlands Hospital. 18 th Annual Conference of the British HIV Association (BHIVA)
18 th Annual Conference of the British HIV Association (BHIVA) Dr Sophia Davies Birmingham Heartlands Hospital 18-20 April 2012, The International Convention Centre, Birmingham 18 th Annual Conference
More informationCLL: A Guide for Patients and Caregivers CHRONIC LYMPHOCYTIC LEUKEMIA
CLL: A Guide for Patients and Caregivers LEUKEMIA LYMPHOMA CHRONIC LYMPHOCYTIC LEUKEMIA MYELOMA Introduction In the U.S. In 2006, about 91,000 people were living with CLL In 2007, more than 15,000 people
More informationGazyva (obinutuzumab)
STRENGTH DOSAGE FORM ROUTE GPID 1000mg/40mL Vial Intravenous 35532 MANUFACTURER Genentech, Inc. INDICATION(S) Gazyva (obinutuzumab) is a CD20- directed cytolytic antibody and is indicated, in combination
More informationStem Cell Transplantation for Severe Aplastic Anemia
Number of Transplants 10/24/2011 Stem Cell Transplantation for Severe Aplastic Anemia Claudio Anasetti, MD Professor of Oncology and Medicine Chair, Blood and Marrow Transplant Dpt Moffitt Cancer Center
More informationNIH Public Access Author Manuscript Leuk Lymphoma. Author manuscript; available in PMC 2015 February 27.
NIH Public Access Author Manuscript Published in final edited form as: Leuk Lymphoma. 2013 January ; 54(1): 174 176. doi:10.3109/10428194.2012.691484. Transformed large B-cell lymphoma in rituximab-allergic
More informationSkin Pathway Group Alemtuzumab in Cutaneous Lymphoma
Skin Pathway Group Alemtuzumab in Cutaneous Lymphoma Indication: Treatment of patients with Cutaneous Lymphoma (Unlicensed use) Disease control prior to Reduced Intensity Conditioning Stem Cell Transplant
More informationHYPER IgM SYNDROME This booklet is intended for use by patients and their families and should not replace advice from a clinical immunologist.
HYPER IgM SYNDROME This booklet is intended for use by patients and their families and should not replace advice from a clinical immunologist. 1 HYPER IgM SYNDROME Also available : COMMON VARIABLE IMMUNODEFICIENCY
More informationMulti-Virus-Specific T cell Therapy for Patients after HSC and CB Transplant
Multi-Virus-Specific T cell Therapy for Patients after HSC and CB Transplant Hanley PJ, Krance BR, Brenner MK, Leen AM, Rooney CM, Heslop HE, Shpall EJ, Bollard CM Hematopoietic Stem Cell Transplantation
More informationLymphatic system component
Introduction Lymphatic system component Statistics Overview Lymphoma Non Hodgkin s Lymphoma Non- Hodgkin's is a type of cancer that originates in the lymphatic system. It is estimated to be the sixth most
More informationThe future of HSCT. John Barrett, MD, NHBLI, NIH Bethesda MD
The future of HSCT John Barrett, MD, NHBLI, NIH Bethesda MD Transplants today Current approaches to improve SCT outcome Optimize stem cell dose and source BMT? PBSCT? Adjusting post transplant I/S to minimize
More informationWaldenstrom s Macroglobulinemia
Waldenstrom s Macroglobulinemia : Monoclonal Antibodies Introduction Waldenstrom s macroglobulinemia (WM) is a lymphoma, or cancer of the lymphatic system. It occurs in a type of white blood cell called
More informationLimitations of EBV PCR monitoring to detect EBV associated post-transplant lymphoproliferative disorder
Pediatr Transplantation 2003: 7: 223 227 Printed in UK. All rights reserved Copyright Ó 2003 Blackwell Munksgaard Pediatric Transplantation ISSN 1397-3142 Limitations of EBV PCR monitoring to detect EBV
More informationLymphoma is a cancer that develops in the white blood cells (lymphocytes) of the lymphatic system, which is part of the body's immune system.
Scan for mobile link. Lymphoma Lymphoma is a cancer that develops in the white blood cells of the lymphatic system. Symptoms may include enlarged lymph nodes, unexplained weight loss, fatigue, night sweats
More informationPBMC from each patient were suspended in AIM V medium (Life Technologies) with 5%
Allogeneic T-cells expressing an anti-cd19 chimeric antigen receptor induce remissions of B-cell malignancies that progress after allogeneic hematopoietic stem cell transplantation without causing graft-versus-host
More informationThe how and why of Acute HIV Infection 1. How do we best diagnosis patients with acute HIV?
Acute HIV infection Eric Rosenberg, MD Associate Professor of Pathology Director, Clinical Microbiology Laboratory Massachusetts General Hospital Harvard Medical School The how and why of Acute HIV Infection
More informationHuman Herpes Virus-6 Limbic Encephalitis
Case Studies [1] March 19, 2013 Case history: A 32-year-old Caucasian female with newly diagnosed acute myeloid leukemia (AML) was treated with induction chemotherapy and attained complete remission. She
More informationInfection and Immune Reconstitution: The NEW Forms
Infection and Immune Reconstitution: The NEW Forms Marcie Tomblyn, MD, MS Assistant Professor, UMN Assistant Scientific Director, CIBMTR Minneapolis February 16, 2006 Why the changes? Infection data not
More informationLancashire and South Cumbria Haematology NSSG Guidelines for Follicular Lymphoma:
1 Lancashire and South Cumbria Haematology NSSG Guidelines for Follicular Lymphoma: 2018-19 1.1 Pretreatment evaluation The following tests should be performed: FBC, U&Es, creat, LFTs, calcium, LDH, Igs/serum
More informationThis was a multicenter study conducted at 11 sites in the United States and 11 sites in Europe.
Protocol CAM211: A Phase II Study of Campath-1H (CAMPATH ) in Patients with B- Cell Chronic Lymphocytic Leukemia who have Received an Alkylating Agent and Failed Fludarabine Therapy These results are supplied
More informationAppendix I (a) Human Surveillance Case Definition (Revised July 4, 2005)
Section A: Case Definitions Appendix I (a) Human Surveillance Case Definition (Revised July 4, 2005) The current Case Definitions were drafted with available information at the time of writing. Case Definitions
More informationAppendix B: Provincial Case Definitions for Reportable Diseases
Ministry of Health and Long-Term Care Infectious Diseases Protocol Appendix B: Provincial Case Definitions for Reportable Diseases Disease: West Nile Virus Illness Revised March 2017 West Nile Virus Illness
More informationRiposta immune versus stato immune
Riposta immune versus stato immune Russell E. Lewis U.O. Malattie Infettive, Policlinico S. Orsola-Malpighi Dipartimento di Scienze Mediche e Chirurgiche Alma Mater Studiorum Università di Bologna Immunodeficiency
More informationEBV Infection. > Cellular Immune Response Profiling. > Humoral Immune Response Profiling EBV. ImmunoTools
EBV ImmunoTools Peptide Tools to Study EBV EBV Infection > Cellular Immune Response Profiling Antigen spanning EBV PepMix Peptide Pools PepMix Collection EBV > Humoral Immune Response Profiling EBV RepliTope
More informationNON HODGKINS LYMPHOMA: AGGRESSIVE Updated June 2015 by Dr. Manna (PGY-5 Medical Oncology Resident, University of Calgary)
NON HODGKINS LYMPHOMA: AGGRESSIVE Updated June 2015 by Dr. Manna (PGY-5 Medical Oncology Resident, University of Calgary) Reviewed by Dr. Michelle Geddes (Staff Hematologist, University of Calgary) and
More informationMISDIAGNOSED MALIGNANCY IN TRANSPLANTED ORGANS.
MISDIAGNOSED MALIGNANCY IN TRANSPLANTED ORGANS. O. Detry, B. Detroz, M. D'Silva, J.O. Defraigne, M.Meurisse, P.Honore, R. Limet, N. Jacquet. Department of Surgery and Transplantation. CHU Sart-Tilman,
More informationKEYTRUDA is also indicated in combination with pemetrexed and platinum chemotherapy for the
FDA-Approved Indication for KEYTRUDA (pembrolizumab) in Combination With Carboplatin and Either Paclitaxel or Nab-paclitaxel for the Firstline Treatment of Patients With Metastatic Squamous Non Small Cell
More informationRecommendations for VZV management in. Dan Engelhard, Pierre Reusser, Rafael de la Camara, Hermann Einsele, Jan Styczynski, Kate Ward, Per Ljungman
Recommendations for VZV management in patients Cas cliniques with leukemia Dan Engelhard, Pierre Reusser, Rafael de la Camara, Hermann Einsele, Jan Styczynski, Kate Ward, Per Ljungman Introduction Acute
More informationAll Wales Lymphoma Panel Lymphoma Course April 2015 Wales Millennium Centre Cardiff
All Wales Lymphoma Panel Lymphoma Course 23-24 April 2015 Wales Millennium Centre Cardiff Case Histories Online slides at: http://dental.uwcm.ac.uk:82/awlp%20course%202015/view.apml? Professor Sebastian
More informationNew Evidence reports on presentations given at EHA/ICML Bendamustine in the Treatment of Lymphoproliferative Disorders
New Evidence reports on presentations given at EHA/ICML 2011 Bendamustine in the Treatment of Lymphoproliferative Disorders Report on EHA/ICML 2011 presentations Efficacy and safety of bendamustine plus
More informationAn Overview of Blood and Marrow Transplantation
An Overview of Blood and Marrow Transplantation October 24, 2009 Stephen Couban Department of Medicine Dalhousie University Objectives What are the types of blood and marrow transplantation? Who may benefit
More informationLong-term remission in idiopathic Castleman's disease with tocilizumab followed by consolidation with high-dose melphalan-two case studies.
Long-term remission in idiopathic Castleman's disease with tocilizumab followed by consolidation with high-dose melphalan-two case studies. Jerkeman, Mats; Lindén, Ola Published in: European Journal of
More informationIl trapianto di cellule staminali emopoietiche nel paziente portatore di virus epatitici
Il trapianto di cellule staminali emopoietiche nel paziente portatore di virus epatitici Anna Locasciulli Ematologia e Trapianto di Cellule Staminali Emopoietiche Ospedale S.Camillo, Roma Il trapianto
More informationHematology 101. Rachid Baz, M.D. 5/16/2014
Hematology 101 Rachid Baz, M.D. 5/16/2014 Florida 101 Epidemiology Estimated prevalence 8,000 individuals in U.S (compare with 80,000 MM patients) Annual age adjusted incidence 3-8/million-year 1 More
More informationTRANSPLANT IMMUNOLOGY. Shiv Pillai Ragon Institute of MGH, MIT and Harvard
TRANSPLANT IMMUNOLOGY Shiv Pillai Ragon Institute of MGH, MIT and Harvard Outline MHC / HLA Direct vs indirect allorecognition Alloreactive cells: where do they come from? Rejection and Immunosuppression
More informationIVIG (intravenous immunoglobulin) Bivigam, Carimune NF, Flebogamma, Gammagard, Gammagard S/D, Gammaked, Gammaplex, Gamunex-C, Octagam, Privigen
Pre - PA Allowance None Prior-Approval Requirements Diagnoses Patient must have ONE of the following documented indications: 1. Primary Immunodeficiency Disease (PID) with ONE of the a. Hypogammaglobulinemia,
More informationCMV pneumonia in allogeneic BMT recipients undergoing early treatment or pre-emptive ganciclovir therapy
(2000) 26, 413 417 2000 Macmillan Publishers Ltd All rights reserved 0268 3369/00 $15.00 www.nature.com/bmt CMV pneumonia in allogeneic BMT recipients undergoing early treatment or pre-emptive ganciclovir
More informationWaldenstrom s Macroglobulinemia
Waldenstrom s Macroglobulinemia : Introduction Waldenstrom s macroglobulinemia (WM) is a lymphoma, or cancer of the lymphatic system. It occurs in a type of white blood cell called a B-lymphocyte or B-cell,
More informationOsteosclerotic Myeloma (POEMS Syndrome)
Osteosclerotic Myeloma (POEMS Syndrome) Osteosclerotic Myeloma (POEMS Syndrome) Synonyms Crow-Fukase syndrome Multicentric Castleman disease Takatsuki syndrome Acronym coined by Bardwick POEMS Scheinker,
More informationCase Report A case of EBV positive diffuse large B-cell lymphoma of the adolescent
Int J Clin Exp Med 2014;7(1):307-311 www.ijcem.com /ISSN:1940-5901/IJCEM1311029 Case Report A case of EBV positive diffuse large B-cell lymphoma of the adolescent Qilin Ao 2, Ying Wang 1, Sanpeng Xu 2,
More informationUnderstanding your diagnosis. Dr Graham Collins Consultant Haemtologist Oxford University Hospitals
Understanding your diagnosis Dr Graham Collins Consultant Haemtologist Oxford University Hospitals Common questions I get asked What is lymphoma? What subtype do I have and what does that mean? What are
More informationPediatric Oncology. Vlad Radulescu, MD
Pediatric Oncology Vlad Radulescu, MD Objectives Review the epidemiology of childhood cancer Discuss the presenting signs and symptoms, general treatment principles and overall prognosis of the most common
More informationDilemmas in the Management of Meningitis & Encephalitis HEADACHE AND FEVER. What is the best initial approach for fever, headache, meningisums?
Dilemmas in the Management of Meningitis & Encephalitis Paul D. Holtom, MD Professor of Medicine and Orthopaedics USC Keck School of Medicine HEADACHE AND FEVER What is the best initial approach for fever,
More informationMorphology Case Study. Presented by Niamh O Donnell, BSc, MSc. Medical Scientist Haematology Laboratory Cork University Hospital
Morphology Case Study Presented by Niamh O Donnell, BSc, MSc. Medical Scientist Haematology Laboratory Cork University Hospital 41 year old male presented to GP for routine check-up in May 2011. FBC Results:
More informationLEUKAEMIA and LYMPHOMA. Dr Mubarak Abdelrahman Assistant Professor Jazan University
LEUKAEMIA and LYMPHOMA Dr Mubarak Abdelrahman Assistant Professor Jazan University OBJECTIVES Identify etiology and epidemiology for leukemia and lymphoma. Discuss common types of leukemia. Distinguish
More informationCorporate Medical Policy
Corporate Medical Policy Hematopoietic Stem-Cell Transplantation for Waldenstrom Macroglobulinemia File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_stem_cell_transplantation_for_waldenstrom_macroglobulinemia
More informationNON- HODGKIN LYMPHOMA
NON- HODGKIN LYMPHOMA non - Hodgkin lymphoma This medical guide is designed for educational purposes to help patients understand. Please consult your doctor on specific questions and details about your
More information